MarketAlert – Real-Time Market & Crypto News, Analysis & AlertsMarketAlert – Real-Time Market & Crypto News, Analysis & Alerts
Font ResizerAa
  • Crypto News
    • Altcoins
    • Bitcoin
    • Blockchain
    • DeFi
    • Ethereum
    • NFTs
    • Press Releases
    • Latest News
  • Blockchain Technology
    • Blockchain Developments
    • Blockchain Security
    • Layer 2 Solutions
    • Smart Contracts
  • Interviews
    • Crypto Investor Interviews
    • Developer Interviews
    • Founder Interviews
    • Industry Leader Insights
  • Regulations & Policies
    • Country-Specific Regulations
    • Crypto Taxation
    • Global Regulations
    • Government Policies
  • Learn
    • Crypto for Beginners
    • DeFi Guides
    • NFT Guides
    • Staking Guides
    • Trading Strategies
  • Research & Analysis
    • Blockchain Research
    • Coin Research
    • DeFi Research
    • Market Analysis
    • Regulation Reports
Reading: Precipio Announces Q2-2025 Shareholder Update Call
Share
Font ResizerAa
MarketAlert – Real-Time Market & Crypto News, Analysis & AlertsMarketAlert – Real-Time Market & Crypto News, Analysis & Alerts
Search
  • Crypto News
    • Altcoins
    • Bitcoin
    • Blockchain
    • DeFi
    • Ethereum
    • NFTs
    • Press Releases
    • Latest News
  • Blockchain Technology
    • Blockchain Developments
    • Blockchain Security
    • Layer 2 Solutions
    • Smart Contracts
  • Interviews
    • Crypto Investor Interviews
    • Developer Interviews
    • Founder Interviews
    • Industry Leader Insights
  • Regulations & Policies
    • Country-Specific Regulations
    • Crypto Taxation
    • Global Regulations
    • Government Policies
  • Learn
    • Crypto for Beginners
    • DeFi Guides
    • NFT Guides
    • Staking Guides
    • Trading Strategies
  • Research & Analysis
    • Blockchain Research
    • Coin Research
    • DeFi Research
    • Market Analysis
    • Regulation Reports
Have an existing account? Sign In
Follow US
© Market Alert News. All Rights Reserved.
  • bitcoinBitcoin(BTC)$66,398.00-0.83%
  • ethereumEthereum(ETH)$1,945.09-0.74%
  • tetherTether(USDT)$1.000.00%
  • rippleXRP(XRP)$1.36-1.28%
  • binancecoinBNB(BNB)$601.84-1.50%
  • usd-coinUSDC(USDC)$1.000.01%
  • solanaSolana(SOL)$79.28-1.53%
  • tronTRON(TRX)$0.277820-0.35%
  • dogecoinDogecoin(DOGE)$0.0934660.95%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.04-0.38%
Press Releases

Precipio Announces Q2-2025 Shareholder Update Call

Last updated: August 1, 2025 3:20 am
Published: 7 months ago
Share

Conference Call to be held on August 14th, 2025 at 5:00 PM EST

NEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses.

The conference call may be accessed by calling 800.717.1738. All callers should ask for the Precipio conference call.

Listeners interested in submitting questions in advance should email their questions to [email protected] and management will do its best to address those questions during the call.

A replay of the call will be available approximately 24 hours after the call and may be accessed via the Investors page on Precipio’s website, https://www.precipiodx.com/investors/.

Get the latest news

delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.

Advertisement

Availability of Other Information About Precipio

For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Advertisement

CONTACT: Inquiries:

[email protected]

+1-203-787-7888 Ext. 523

Advertisement

Read more on The Manila times

This news is powered by The Manila times The Manila times

Share this:

  • Share on X (Opens in new window) X
  • Share on Facebook (Opens in new window) Facebook

Like this:

Like Loading...

Related

BlockDAG V4 Dashboard, XRP Price Volatility, & Solana Growth Update
innoscripta SE / DE000A40QVM8
AIA Singapore partners with Amplify Health to tackle Singapore’s most common chronic illnesses by bringing personalised chronic disease management to Singaporeans
Heidelberg Materials AG / DE0006047004
Original-Research: PNE AG (von First Berlin Equity Research GmbH): Buy – boerse.de

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Email Copy Link Print
Previous Article Real Deal – Daily Times
Next Article MSCI Inc.: MSCI August Index Review Announcement Scheduled for August 07, 2025
© Market Alert News. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Prove your humanity


Lost your password?

%d